Browse CASP3

Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain -
Function

Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspase-6, -7 and -9. Involved in the cleavage of huntingtin. Triggers cell adhesion in sympathetic neurons through RET cleavage.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0000737 DNA catabolic process, endonucleolytic
GO:0001101 response to acid chemical
GO:0001666 response to hypoxia
GO:0002237 response to molecule of bacterial origin
GO:0002262 myeloid cell homeostasis
GO:0006308 DNA catabolic process
GO:0006309 apoptotic DNA fragmentation
GO:0006914 autophagy
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0006921 cellular component disassembly involved in execution phase of apoptosis
GO:0006979 response to oxidative stress
GO:0007611 learning or memory
GO:0008544 epidermis development
GO:0008635 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c
GO:0009314 response to radiation
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009913 epidermal cell differentiation
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010165 response to X-ray
GO:0010212 response to ionizing radiation
GO:0010506 regulation of autophagy
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0016236 macroautophagy
GO:0016241 regulation of macroautophagy
GO:0019439 aromatic compound catabolic process
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021761 limbic system development
GO:0021766 hippocampus development
GO:0030099 myeloid cell differentiation
GO:0030216 keratinocyte differentiation
GO:0030218 erythrocyte differentiation
GO:0030220 platelet formation
GO:0030262 apoptotic nuclear changes
GO:0030900 forebrain development
GO:0031960 response to corticosteroid
GO:0032025 response to cobalt ion
GO:0032355 response to estradiol
GO:0032496 response to lipopolysaccharide
GO:0034101 erythrocyte homeostasis
GO:0034284 response to monosaccharide
GO:0034349 glial cell apoptotic process
GO:0034612 response to tumor necrosis factor
GO:0034655 nucleobase-containing compound catabolic process
GO:0035094 response to nicotine
GO:0035329 hippo signaling
GO:0036293 response to decreased oxygen levels
GO:0036344 platelet morphogenesis
GO:0038034 signal transduction in absence of ligand
GO:0038179 neurotrophin signaling pathway
GO:0042493 response to drug
GO:0042542 response to hydrogen peroxide
GO:0043200 response to amino acid
GO:0043279 response to alkaloid
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043523 regulation of neuron apoptotic process
GO:0043525 positive regulation of neuron apoptotic process
GO:0043588 skin development
GO:0044270 cellular nitrogen compound catabolic process
GO:0044708 single-organism behavior
GO:0045862 positive regulation of proteolysis
GO:0046677 response to antibiotic
GO:0046700 heterocycle catabolic process
GO:0048011 neurotrophin TRK receptor signaling pathway
GO:0048545 response to steroid hormone
GO:0048872 homeostasis of number of cells
GO:0050890 cognition
GO:0051384 response to glucocorticoid
GO:0051402 neuron apoptotic process
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0070482 response to oxygen levels
GO:0070997 neuron death
GO:0071407 cellular response to organic cyclic compound
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0097194 execution phase of apoptosis
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1901361 organic cyclic compound catabolic process
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0002020 protease binding
GO:0004175 endopeptidase activity
GO:0004190 aspartic-type endopeptidase activity
GO:0004197 cysteine-type endopeptidase activity
GO:0005123 death receptor binding
GO:0005126 cytokine receptor binding
GO:0008047 enzyme activator activity
GO:0008234 cysteine-type peptidase activity
GO:0008656 cysteine-type endopeptidase activator activity involved in apoptotic process
GO:0016004 phospholipase activator activity
GO:0016005 phospholipase A2 activator activity
GO:0016504 peptidase activator activity
GO:0016505 peptidase activator activity involved in apoptotic process
GO:0032813 tumor necrosis factor receptor superfamily binding
GO:0043028 cysteine-type endopeptidase regulator activity involved in apoptotic process
GO:0060229 lipase activator activity
GO:0061134 peptidase regulator activity
GO:0070001 aspartic-type peptidase activity
GO:0097153 cysteine-type endopeptidase activity involved in apoptotic process
GO:0097200 cysteine-type endopeptidase activity involved in execution phase of apoptosis
Cellular Component GO:0031264 death-inducing signaling complex
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04115 p53 signaling pathway
hsa04210 Apoptosis
hsa04650 Natural killer cell mediated cytotoxicity
hsa04668 TNF signaling pathway
hsa04726 Serotonergic synapse
Reactome R-HSA-211227: Activation of DNA fragmentation factor
R-HSA-111459: Activation of caspases through apoptosome-mediated cleavage
R-HSA-109581: Apoptosis
R-HSA-140342: Apoptosis induced DNA fragmentation
R-HSA-351906: Apoptotic cleavage of cell adhesion proteins
R-HSA-111465: Apoptotic cleavage of cellular proteins
R-HSA-75153: Apoptotic execution phase
R-HSA-111471: Apoptotic factor-mediated response
R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway
R-HSA-264870: Caspase-mediated cleavage of cytoskeletal proteins
R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE
R-HSA-111461: Cytochrome c-mediated apoptotic response
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-109606: Intrinsic Pathway for Apoptosis
R-HSA-418889: Ligand-independent caspase activation via DCC
R-HSA-205025: NADE modulates death signalling
R-HSA-5357801: Programmed Cell Death
R-HSA-111463: SMAC binds to IAPs
R-HSA-111469: SMAC-mediated apoptotic response
R-HSA-111464: SMAC-mediated dissociation of IAP
R-HSA-162582: Signal Transduction
R-HSA-2028269: Signaling by Hippo
R-HSA-449147: Signaling by Interleukins
R-HSA-166520: Signalling by NGF
R-HSA-211736: Stimulation of the cell death response by PAK-2p34
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CASP3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CASP3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24937677Breast CarcinomaPromote immunityContrary to ILC, IDC patients frequently expressed higher cleaved caspase-3 and Ki67, which was prognostic.
24913717breast carcinomaPromote immunity (T cell function); increase the efficacy of immunotherapyLow doses of c-di-GMP significantly increased the production of IL12 by MDSCs, in correlation with improved T-cell responses to Mage-b, whereas a high dose of c-di-GMP (range, 0.3-3 mmol/L) activated caspase-3 in the 4T1 tumor cells and killed the tumor cells directly.
25209187colorectal carcinomaPromote immunityDetailed analysis of the mechanisms underlying CPT11 and 5FU adverse effects and the affected pathways revealed that in colorectal cancer mice, 5FU reduced MDSC levels, both by inducing their apoptotic death and by enforcing myeloid cell differentiation to mature macrophages and dendritic cells. The former drug effect is associated with elevated levels of cleaved caspase-3 and the latter involves a decreased expression of the proinflammatory S100A8/9 proteins, known to induce MDSC differentiation arrest
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CASP3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CASP3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0360.896
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.160.937
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0430.974
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4330.233
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3650.768
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5220.714
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.090.808
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0250.987
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1610.926
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1870.867
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6350.716
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1150.0892
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CASP3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CASP3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CASP3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CASP3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CASP3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CASP3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CASP3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCASP3
Namecaspase 3, apoptosis-related cysteine peptidase
Aliases CPP32; CPP32B; Yama; apopain; caspase 3, apoptosis-related cysteine protease; SCA-1; CASP-3; CPP-32; PARP cl ......
Chromosomal Location4q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CASP3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CASP3.
ID Name Drug Type Targets #Targets
DB01017MinocyclineSmall MoleculeALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA7
DB031245-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic AcidSmall MoleculeCASP31
DB05408EmricasanSmall MoleculeCASP1, CASP3, CASP73
DB068622-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACIDSmall MoleculeCASP31
DB07696methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoateSmall MoleculeCASP31
DB082131-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONESmall MoleculeCASP31
DB08229[N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACIDSmall MoleculeCASP31
DB082514-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACIDSmall MoleculeCASP31
DB08497(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetateSmall MoleculeCASP31
DB08498(1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetateSmall MoleculeCASP31
DB08499N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamideSmall MoleculeCASP31